Medigene AG (PK) 뉴스 - MDGEF | 주식 OTC 시장

개인 투자자를 위한 전문가급 도구.

3-Months Report: MediGene AG Reduces Net Loss by 84%

3-Months Report: MediGene AG Reduces Net Loss by 84% - Fivefold increase in revenues from 0.7 million euro to 3.9 million euro MARTINSRIED...

MediGene's First Drug Eligard(R) Is Launched

MediGene's First Drug Eligard(R) Is Launched * Marketing partner Yamanouchi launched cancer drug Eligard(R) in Germany today. MARTINSRIED, Germany...

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule Expanding Market...

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for Actinic Keratosis...

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial MARTINSRIED...

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial * Data indicate high and lasting efficacy as...

게시물을 찾을 수 없습니다

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Medigene AG (PK) (MDGEF)

개인 투자자를 위한 전문가급 도구.

MDGEF 뉴스

3-Months Report: MediGene AG Reduces Net Loss by 84%

MediGene's First Drug Eligard(R) Is Launched

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Medigene AG (PK) (MDGEF) 뉴스

Medigene AG (PK) (MDGEF)

개인 투자자를 위한 전문가급 도구.

MDGEF 뉴스

3-Months Report: MediGene AG Reduces Net Loss by 84%

MediGene's First Drug Eligard(R) Is Launched

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거